Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. WAVE Life Sciences's
Operating Income
for the
three
months ended in Dec. 2024 was €21.9 Mil. WAVE Life Sciences's Interest Expense for the
three
months ended in Dec. 2024 was €0.0 Mil.
GuruFocus does not calculate 's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. WAVE Life Sciences Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for WAVE Life Sciences's Interest Coverage or its related term are showing as below:
STU:1U5's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 112.88 * Ranked among companies with meaningful Interest Coverage only.
WAVE Life Sciences Interest Coverage Historical Data
The historical data trend for WAVE Life Sciences's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of WAVE Life Sciences's Interest Coverage
For the Biotechnology subindustry, WAVE Life Sciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences's Interest Coverage Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Interest Coverage distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
GuruFocus does not calculate WAVE Life Sciences's interest coverage with the available data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences (STU:1U5) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
WAVE Life Sciences Interest Coverage Related Terms
Thank you for viewing the detailed overview of WAVE Life Sciences's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:1U5 has been successfully added to your 